Early pancreatic cancer study reports tumour responses in 61-patient group
Revolution Medicines reported confirmed responses in 60.7% of participants given daraxonrasib with chemotherapy. A larger comparative trial is ongoing.

In an early-stage study of 61 people with previously untreated metastatic pancreatic adenocarcinoma, 60.7% had a confirmed tumour response after receiving daraxonrasib with two chemotherapy drugs, Revolution Medicines reported. Complete responses were recorded in 8.2% of participants. A complete response describes what was measurable on scans at assessment and does not establish that the cancer was cured.
Participants in that group all received the combination, so the results cannot show what daraxonrasib adds to chemotherapy alone. The sponsor reported estimated survival of 76.6% at 12 months and a median follow-up of 18.3 months. The data were presented at the ENA meeting in Barcelona on 20 November.
The U.S. Food and Drug Administration approved daraxonrasib in August for adults with metastatic pancreatic adenocarcinoma who had previously received systemic treatment or could not receive multiagent systemic treatment. The study reported this week concerns a different question: using the combination as initial treatment. The phase 3 RASolute 303 trial is testing daraxonrasib with and without chemotherapy against chemotherapy alone in that setting.
Sources
- Early pancreatic cancer study reports tumour responses in 61-patient group — Revolution Medicines
- FDA approval and indication — U.S. Food and Drug Administration
- Assigned writer
- Jack ThompsonCredit pending confirmation
- Assigned reviewer
- Sophie TaylorReview pending